ArticleClinical and experimental gastroenterology2010
Role of prucalopride, a serotonin (5-HT(4)) receptor agonist, for the treatment of chronic constipation.
Article in Clinical and experimental gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- Fermented Gold Kiwi Improves Gastrointestinal Motility and Functional Constipation: An Animal Study and Human Randomized Clinical Test.Nutrients · 2024Trial
- Effect of prucalopride to improve time to gut function recovery following elective colorectal surgery: randomized clinical trial.The British journal of surgery · 2022Trial
- YH12852, a Potent and Selective Receptor Agonist of 5-hydroxytryptamine, Increased Gastrointestinal Motility in Healthy Volunteers and Patients With Functional Constipation.Clinical and translational science · 2021Trial
- Dup15q model mice exhibit impaired gastrointestinal motility and a constipation-like phenotype, alleviated by prucalopride.Translational psychiatry · 2026Article
- Pathophysiological mechanisms, diagnostic innovations, and multimodal therapeutic strategies for slow transit constipation.BMC gastroenterology · 2025Review
- Novel, small molecules targeting the 5-HTbioRxiv : the preprint server for biology · 2025Article
- Article
- Lubiprostone Improves Distal Segment-Specific Colonic Contractions through TRPC4 Activation Stimulated by EP3 Prostanoid Receptor.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Serotonin receptor-mediated vasorelaxation occurs primarily through 5-HTPhysiological reports · 2024Article
- Clinical utility of colon capsule endoscopy: a moving target?Therapeutic advances in gastroenterology · 2023Review
- Comparison of laxative effects of fermented soybeans (Nutrition research and practice · 2022Article
- Article
- Current Opinion on Prucalopride in Gastroparesis and Chronic Constipation Treatment: A Focus on Patient Selection and Safety.Therapeutics and clinical risk management · 2021Review
- Article
- A quantitative systems pharmacology model of colonic motility with applications in drug development.Journal of pharmacokinetics and pharmacodynamics · 2019Article
- New developments in the treatment of opioid-induced gastrointestinal symptoms.United European gastroenterology journal · 2018Review
- Expert consensus on the assessment and treatment of chronic constipation in the elderly.Aging medicine (Milton (N.S.W)) · 2018Article
- Colon Capsule Visualization Is Not Enhanced with Prucalopride: A Randomized Controlled Trial.Journal of the Canadian Association of Gastroenterology · 2018Article
- Machine Learning of Human Pluripotent Stem Cell-Derived Engineered Cardiac Tissue Contractility for Automated Drug Classification.Stem cell reports · 2017Article
- An update on prucalopride in the treatment of chronic constipation.Therapeutic advances in gastroenterology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Constipation affects up to a quarter of the population in developed countries and is associated with poor quality of life and significant economic burden. Many patients with chronic constipation are dissatisfied with current therapy due to lack of long-term efficacy or side effects. Previous nonselective 5-hydroxytryptamine receptor 4 (5-HT(4)) agonists have been associated with significant interactions with other receptors (5-HT(1B), 5-HT(1D), and 5-HT(2B) for tegaserod; hERG for cisapride), leading to adverse cardiovascular events resulting in withdrawal of these drugs from the market. Prucalopride is a novel gastrointestinal prokinetic agent. It acts as a high affinity, highly-selective 5-HT(4) agonist. Its efficacy in patients with chronic constipation has been demonstrated in several phase II and phase III clinical trials showing significant improvements in bowel transit, bowel function, gastrointestinal symptoms, and quality of life, with benefit maintained for up to 24 months in open label, multicenter, follow-up studies. Prucalopride's high selectivity for the 5-HT(4) receptor may explain its favorable safety and tolerability profiles, even in elderly subjects with stable cardiovascular disease. Prucalopride is a well tolerated and efficacious prokinetic medication that should enhance the treatment of chronic constipation unresponsive to first-line treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.